Expanded Olumiant coverage still falls short of patient expectations

Patients call for lower reimbursement barriers, citing strict requirements for prior treatment and disease severity

Public opinion collection period to end on June 22…medical community also warns of limited coverage

Although Lilly Korea’s Olumiant (baricitinib) has achieved broader reimbursement coverage for severe alopecia areata, the criteria remain a point of contention among patients, who argue that the current guidelines require more reasonable adjustments.

The medical community also warns that many patients who have long awaited reimbursement coverage may still face limited access to the high reimbursement standards.

According to industry sources on June 24, numerous patient complaints were submitted during the public comment period on Olumiant’s proposed reimbursement criteria for severe alopecia areata, which concluded on June 22.

Under the proposed reimbursement criteria, patients must satisfy two requirements to qualify for insurance coverage. First, they must have received at least three months of treatment with conventional therapies such as systemic corticosteroids or cyclosporine without achieving at least a 30% reduction in disease severity, as measured by the Severity of Alopecia Tool (SALT), or they must have been unable to continue treatment because of adverse effects.

To qualify as having severe disease, patients must either have a SALT score of 50 or higher, or have both eyebrows and eyelashes completely absent or clearly interrupted with a SALT score between 20 and less than 50.

To maintain reimbursement, patients must achieve a SALT score of 20 or lower at the initial assessment conducted at Week 36.Thereafter, reimbursement eligibility will be reassessed every six months to confirm maintenance of the initial treatment response, with reimbursement limited to a maximum of 2 years.

Patients argue that because severe alopecia areata is a chronic autoimmune disease with a high likelihood of recurrence, limiting reimbursement to two years is insufficient.

One patient who submitted an opinion during the public consultation stated, “Rather than imposing a uniform two-year limit, reimbursement should be extended based on periodic evaluations of SALT scores and patients' clinical status.”

Previously non-reimbursed patients face 2 reimbursement criteria barriers

The proposed policy also includes transitional provisions for patients who have been receiving Olumiant at their own expense. However, these patients must demonstrate that they met the current reimbursement criteria when treatment was initiated. To do so, they must provide evidence such as prior treatment history and photographs documenting disease severity.

The issue is that patients must satisfy both requirements: ▲prior treatment history and ▲ disease severity. Patients who began Olumiant based solely on severity without prior treatment, or those who underwent prior treatment but lack adequate documentation of disease severity at that time, would not qualify for reimbursement.

Critics argue that satisfying both requirements is excessively burdensome for the patients because patients with autoimmune diseases often experience interruptions in treatment over several years or receive care at multiple medical institutions.

Another patient who submitted comments stated, “The policy is essentially telling patients to stop treatment, wait until their condition worsens again, and then receive reimbursement for retreatment,” and criticized the proposal as being out of touch with reality.

The medical community also expressed concern that the proposed reimbursement criteria could substantially restrict patient access.

Professor Chang-Hun Huh of the Department of Dermatology at Seoul National University Bundang Hospital said, “Patients with severe forms of alopecia like alopecia totalis and alopecia universalis were in such desperate need as they have exhausted all known treatment options. It is disheartening for us as medical professionals because the current reimbursement criteria may actually limit the benefits for patients that have long awaited reimbursmenet, especially to those who have already been receiving treatment.